REVIEWERS' COMMENTS TO AUTHORS:
Thank you for giving me the opportunity to review this manuscript dealing with a topic of high interest to me. In general, I found the research question interesting as validation studies are important issues before analyzing administrative healthcare databases. The study has the merits of including several Italian areas. However, some methodological issues should be dealt with. My major comment is that the authors could consider estimating the positive predictive values for colon and rectal cancers. Regarding sensitivity, it would have been preferable to use registry data as a reference, such as Registro Tumori Regione Campania.
Major comments:
In this study, I understood that the sample was constituted from hospitalized patients with a diagnosis code of cancer in the discharge abstract. It is of course possible to estimate the probability of being a true case among this sample, which represents in my opinion the positive predictive value. I am not sure whether the sensitivity, which is the probability of having the diagnosis code of cancer in the discharge abstract among ascertained cancer cases could be estimated from this sample. I wonder if it would have been preferable to use registry data as a reference. As the authors have access to the Registro Tumori Regione Campania, it might have been useful to perform a supplementary analysis by estimating sensitivity only from this registry data, considered as the gold standard.
Regarding specificity, I am not sure to understand why the controls were chosen from the patients presenting with another cancer. Thus, I wonder if the coding regarding cancers may be better when performed by clinicians specialized in cancerology? Is there any knowledge about this potential bias? (page 7, lines 19-24) -Page 8, « Statistical analysis »: Considering the differences between the sensitivity results (and the difficulty in this estimation when one does not systematically have registry data as a reference) it is important to present also the PPV and the NPV in this validation study. Nevertheless, these results are very useful for the readers, even if their values vary as a function of the prevalence.
General comments:
Introduction Section: The introduction is written clearly. The purpose and the field of the study are well presented.
Methods Section: -Some supplementary elements on the Italian databases would help the reader's understanding. Notably, the authors may explain that there are two regional databases and one local database (page 6, first paragraph) Are the databases inter-linked by a unique number for an individual subject?
-The protocol was previously published but the elements given in the publication are not always sufficient for understanding the methodology. Some supplementary information should be provided to allow the readers to evaluate the validity of the study.
-Page 7, line 30: How was the randomisation performed? Did the method permit a standardisation of randomisation? -Page 7, 2nd paragraph: We lack information concerning the linkage between the studied databases and the medical records. On what information does this linkage depend? Which method was employed? -For validating the methodology in this study, it is important to state the level of professional expertise of the data collectors, how many were they and the elements that ensured a standardization of the data collection. Is it the same for the study of non-cases? How many oncologists studied each case? -Page 7, line 50: Placing the results of K statistics in the "Results" section would be more conventional. -Page 8, last paragraph: The authors state that some data were missing for some medical records; why was the number of required records not increased in order to obtain the suitable number? Results Section: The presentation of tables is not in a conventional format. Various types of information are missing for the results: Table 1 : -The corresponding information in the parentheses is not provided except for age. Is it possible to provide this information for the other variables? Table 2 and Table 3 are not mentioned in the text. Table 3 : The codes for colon cancer and rectal cancer do not correspond to those mentioned previously, neither in the Methods nor in Table 1 . -It is surprising that the incident cases represent more than 80% of the incidents in Umbria, whereas they are around 50% for Napoli et Venezia. Can you explain these results? (Figure 1: 1725 (Figure 1: / 1960 for Umbria) -Page 9, line 18: The successive number of incident cases for the three databases are barely legible. A different presentation would be helpful for reading. It is the same for the confidence intervals. -Pages 9 and 10, last paragraphs: It seems that there is an inversion of the values of specificity and sensitivity between the rectal cancer and the colon cancer; the results in the text and Figure  2 are different. -Page 10, line 22: In order to maintain a consistent presentation, it is necessary to include the 95% CI in parenthesis.
-Page 10, line 42: The term « prevalent subgroup » can bring confusion to the presented incident cases. The sentence should be reformulated.
Discussion Section: -In addition, it could be interesting to discuss the difference between the presented study and the one from Piedmont Hospital even though the studied codes are identical. What could this difference be due to? -The presented results are very impressive and superior to other validation studies. Once again, it would be very interesting to present the organisational modalities regarding the data collection (of control and others) that could perhaps explain such results. -Page 12, line 29: It is necessary to include one or more references at the end of this sentence «Previously, researchers have evaluated the accuracy of colon or rectal cancer diagnosis in administrative databases.» -Page 13, line 27: The capital « I » should be replaced for « instead ». -Page 13, line 42: The presented limitation does not constitute a methodological limitation of the study. We request the authors to present the outcome of their reflection and critique regarding their study.
Conclusion Section: It would be worthwhile mentioning that this study's contribution concerns three areas (Umbria and Napoli regions and Venezia locality) in Italy and that the results may not be generalizable into other settings.
REVIEWER
Alastair Munro University of St Andrews, Scotland REVIEW RETURNED 10-Jan-2018
GENERAL COMMENTS
This paper reports on a validation study of coding for colorectal cancer in 3 regionally based cancer registries in Italy. Patients' case notes were used as the standard against which the accuracy of coding was assessed. The study used randomly selected subsets of patients diagnosed between 2012 and 2014. There were 10207 patients diagnosed with colorectal cancer during the study period, 755 randomly selected patients had case-notes available for review and validation. A total of 560 patients who had cancers coded as arising at non-colorectal sites were used as "controls".
I am unconvinced that the control group that was chosen was appropriate. Patients who were not coded as having cancer might, on review of case-notes, be found to have colorectal cancer. There is no evidence that the authors used age and gender (or any other demographic factors) to match cases (colorectal cancer) with controls.
The authors' primary concern appears to be the demonstration that -amongst patients coded as having cancers other than colorectal cancer -there were very few patients who, upon review of their case-notes, were found to have colorectal cancer. Based on the information summarised in table 3, only 7/560 (1.25%) were misclassified ("false negatives").
However, the data presented in Table 3 The conclusion that I would draw from this study is that almost 1 in 5 of the patients registered as having colorectal cancer did not, in fact, have any positive evidence of the disease. Furthermore 65/755(8.6%) had unequivocal evidence that they had benign disease. If nearly 10% of patients in these registries have benign disease, then this will artificially inflate any estimates of survival from colorectal cancer based on incidence data provided by these registries. None of these important points are addressed in the discussion.
There is no mention of ethical review or permission for access to personal data.
There are several typos, unclear expressions, and cut and paste errors in the manuscript. Another reason is that that cancer registries, at least in our setting, capture data from our administrative databases, and subsequently professionals from the cancer registry department revise the medical charts. Hence, medical charts remain the primary source to confirm the presence of a disease.
Major comments:
-In this study, I understood that the sample was constituted from hospitalized patients with a diagnosis code of cancer in the discharge abstract. It is of course possible to estimate the probability of being a true case among this sample, which represents in my opinion the positive predictive value. ** Our initial aim was to calculate specificity and sensitivity. We calculated the predictive values by means of 2x2 tables.
-I am not sure whether the sensitivity, which is the probability of having the diagnosis code of cancer in the discharge abstract among ascertained cancer cases could be estimated from this sample. I wonder if it would have been preferable to use registry data as a reference. As the authors have access to the Registro Tumori Regione Campania, it might have been useful to perform a supplementary analysis by estimating sensitivity only from this registry data, considered as the gold standard. **To calculate sensitivity we need to have subjects with confirmed cancer disease (as defined by our case ascertainment criteria) as part of all the subjects with cancer disease, i.e., TP/(TP+FN). This can be obtained either using medical charts -which is the best reference standard -or cancer registry (population-based cancer registries in our settings in fact receive electronic data from, administrative databases and verify the presence of disease by consulting medical charts).
There are several studies that used ICD-9 codes from administrative databases as index test and medical charts as reference standard (Benchimol, JCE 2011; 64(8):821-9 ). An approach that is very useful in areas not covered by population-based cancer registries. The suggestion of performing supplementary analyses to assess sensitivity using cancer registries as reference standard is a quite interesting issue and can be addressed in the next future. However, this project (that was approved by the appropriate ethical committees) has received funding from the Italian Ministry of Health and we must therefore adhere to the project proposal.
-Regarding specificity, I am not sure to understand why the controls were chosen from the patients presenting with another cancer. Thus, I wonder if the coding regarding cancers may be better when performed by clinicians specialized in cancerology? Is there any knowledge about this potential bias? (page 7, lines 19-24) **The methodology of the present study is that of a diagnostic accuracy study that usually aims to determine the accuracy of a test clinical settings (Knottnerus DOI: 10.1002/9781444300574.ch2). This methodology is also used in validation studies of administrative databases (Benchimol, JCE 2011; 64(8) :821-9) and it requires that the discriminatory power of a test (ICD-9) is compared to a reference standard (medical chart). Cases are those with the disease of interest and non-cases (controls) are those who do not have the disease. Of course, beyond the fact that controls are those without the disease there is no specific rule for how the control can be selected. We opted to follow the same pattern with which we identified the cases. We are aware that this approach might somehow be "arbitrary" but we are not aware of ideal situations to select controls in studies like ours. In theory, we could have selected any population in the administrative database and this would decrease the chance of identifying a false negative which was not our primary concern.
-Page 8, « Statistical analysis »: Considering the differences between the sensitivity results (and the difficulty in this estimation when one does not systematically have registry data as a reference) it is important to present also the PPV and the NPV in this validation study. Nevertheless, these results are very useful for the readers, even if their values vary as a function of the prevalence. ** We thank dr. Quantin for this suggestion. We agree and have added (statistical methods and result sections) the predictive values with their CIs to the text as suggested.
General comments:
Methods Section: -Some supplementary elements on the Italian databases would help the reader's understanding. Notably, the authors may explain that there are two regional databases and one local database (page 6, first paragraph) ** We thank dr. Quantin. We have added this information to the text: "The administrative databases target of the present study were two regional databases and one local database, representing the Umbria Region (890,000 residents), the Local Health Unit 3 of Napoli (NA) (1,170,000 residents) and the Friuli Venezia Giulia (FVG) Region (1,227,000 residents)".
-Are the databases inter-linked by a unique number for an individual subject? **Any resident in any part of Italy has a unique identification number. The three databases are potentially linkable but at the stage of the present project the assessment was made separately, using the same methodological approach.
-The protocol was previously published but the elements given in the publication are not always sufficient for understanding the methodology. Some supplementary information should be provided to allow the readers to evaluate the validity of the study. **In hindsight we agree that the text should be improved regarding the process of identifying new cases and that this process, performed within each unit, is identical for each unit. The same amendments were made also for the controls. We have changed the methods section as follows: "In each administrative database, patients with occurrence of diagnosis of colorectal cancer between 1 January 2012 and 31 December 2014 were identified using the ICD-9-CM codes located in primary position of the hospital discharge: (a) 153.x for colon cancer, and (b) 154.0, 154.1 and 154.8 for rectal cancer To obtain a cohort of first cases in primary position, records subsequent to the index date were deleted. Subsequently, prevalent cases, that is, those with the same diagnosis (ICD-9-CM codes 153.x or 154.0, 154.1 and 154.8 in any position) in the five years (2007) (2008) (2009) (2010) (2011) before the period of interest, were excluded. This cohort represented our target population from which a sample of cases was obtained using a random sampling method. For controls (non-cases), first subjects aged 18 or higher with diagnosis of cancer disease (i.e., patients having in primary position a diagnosis of cancer (ICD-9 140-239) were identified. Subsequently, from this cohort subjects with colorectal cancer (153.x or 154.0, 154.1 and 154.8 in any position) were excluded obtaining a target population for our controls. From this population we obtained a sample of controls using a random sampling method."
-Page 7, line 30: How was the randomisation performed? Did the method permit a standardisation of randomisation? **We used a simple random method.
-Page 7, 2nd paragraph: We lack information concerning the linkage between the studied databases and the medical records. On what information does this linkage depend? Which method was employed? **Thank you for raising this important point. We added the following text in the Methods section (page 6): "The records in the healthcare databases are provided with a code with which it is possible to identify the corresponding medical charts of the patients that are located in secure in archives. The code that identifies the medical charts is generated using several basic codes that take into account the region, the local health unit, the department of admission and other chronologically progressive codes providing a unique identity to the medical chart event at national level and avoiding duplicate cases."
-For validating the methodology in this study, it is important to state the level of professional expertise of the data collectors, how many were they and the elements that ensured a standardization of the data collection. Is it the same for the study of non-cases? How many oncologists studied each case? **Thank you for this comment. We have now provided clarifications regarding these points. All cases were revised a second time by two oncologists and one internist with experience in oncology. Having said this, we do wish to highlight the fact that our purpose is not to show that all cases were true cancer cases. To reach this aim we could have used different sources including subsequent admissions, the archives of histological documentation, chemotherapy, or radiotherapy. Our primary aim was to validate a simple case definition based on two elements that we could retrieve in the primary medical chart and if this could be replicated within other contexts, which is in the interest of the Ministry of Health.
-Page 7, line 50: Placing the results of K statistics in the "Results" section would be more conventional. ** We thank dr. Quantin for this suggestion. We moved the K statistics to the results section.
-Page 8, last paragraph: The authors state that some data were missing for some medical records; why was the number of required records not increased in order to obtain the suitable number? ** We thank dr. Quantin for this question. Although we did not plan to extract a number of additional clinical charts in order to compensate for any missing clinical chart, the number of missing charts was very low for Umbria (colon cancer 1.5% charts missing; rectal cancer 0%; controls 2.1%) and FVG (colon cancer 0% charts missing; rectal cancer 0.8%; controls 0%) and quite low for ASL Napoli 3 Sud (colon cancer 6.9% charts missing; rectal cancer 8.5%; controls 0%). A study population lower than the estimated sample size lead to the same diagnostic accuracy estimates but with broader confidence intervals. Nevertheless, to be more conservative, we decided to present a "worst case" scenario as well, in which the missing charts were considered false positives.
Results Section:
The presentation of tables is not in a conventional format. Various types of information are missing for the results: Table 1 : -The corresponding information in the parentheses is not provided except for age. Is it possible to provide this information for the other variables? ** We thank dr. Quantin. We have added titles to Table 1 sections "N (%)" and provided percentages for all the values presented in the table. Table 2 and Table 3 are not mentioned in the text. ** We have now revised the Tables as necessary and mentioned them in the text. -It is surprising that the incident cases represent more than 80% of the incidents in Umbria, whereas they are around 50% for Napoli et Venezia. Can you explain these results? (Figure 1 : 1725 / 1960 for Umbria) **Thank you for raising this point, it was helpful in amending the text in the figure. This number (1960) covers all the records in primary position and may expresses the repeated times a subject can be admitted to a hospital. This might be different from one geographical area to another. This should be read as "all records in primary position" (instead of all cases in primary position). We have amended the Figure. -Page 9, line 18: The successive number of incident cases for the three databases are barely legible. A different presentation would be helpful for reading. It is the same for the confidence intervals. ** We thank dr. Quantin for this suggestion. We have presented the number of the cases differently and modified the presentation of confidence intervals throughout the text.
-Pages 9 and 10, last paragraphs: It seems that there is an inversion of the values of specificity and sensitivity between the rectal cancer and the colon cancer; the results in the text and Figure 2 are different. ** We thank dr. Quantin for signalling the mistake. We have now amended Figure 2 .
-Page 10, line 22: In order to maintain a consistent presentation, it is necessary to include the 95% CI in parenthesis. **We have now added it.
-Page 10, line 42: The term « prevalent subgroup » can bring confusion to the presented incident cases. The sentence should be reformulated. **We agree and modified the text as follow: "The most common ICD-9-CM subgroup was rectal cancer (154.1), …" Discussion Section: -In addition, it could be interesting to discuss the difference between the presented study and the one from Piedmont Hospital even though the studied codes are identical. What could this difference be due to? **We thank dr. Quantin for this suggestion. We have revised the Discussion in light of this comment as follows: "Another Italian study evaluated the accuracy of colorectal cancer ICD-9 codes using hospital administrative databases in Piedmont province and found a combined sensitivity for colorectal cancer of 72.4% but with a higher positive predictive value (88%) [Baldi 2008] . While their PPV was higher than our findings, the sensitivity was much lower than ours. These discrepancies could be due to the methodological approaches that differed between our study and the Piedmont study. The Piedmont study used the cancer registry as a reference standard, and the population of interest was selected based on an algorithm which was based on a combination of ICD-9 related to malignant neoplasm of the colon, rectum and rectosigmoid junction in primary position as well as in secondary position and any ICD-9-CM procedure code leading to surgical diagnosis-related group payment. Another potential reason for discrepancy between the Piedmont study and ours may be due to the fact that we limited our target population to those who were incident cases but in primary position. In the Piedmont study, the authors also performed a sensitivity analysis by limiting the analysis only to those in primary position but they did not report the data and concluded simply that the analysis did not lead to any gain in PPV which seems to be their primary objective. Another potential explanation could be that the authors did not consult any medical chart and no case definition was elaborated against which to test the presence the disease."
-The presented results are very impressive and superior to other validation studies. Once again, it would be very interesting to present the organisational modalities regarding the data collection (of control and others) that could perhaps explain such results. **The Discussion regarding the other setting in which validation of colorectal cancer is extended to other two studies. In light of considering the PPV we cannot conclude that our results are superior to that of Baldi (Piedmont) and Helqvist (Denmark) -Page 12, line 29: It is necessary to include one or more references at the end of this sentence «Previously, researchers have evaluated the accuracy of colon or rectal cancer diagnosis in administrative databases.» **We included the references of the studies described below.
-Page 13, line 27: The capital « I » should be replaced for « instead ». **Thank you, we have amended this.
-Page 13, line 42: The presented limitation does not constitute a methodological limitation of the study. We request the authors to present the outcome of their reflection and critique regarding their study. We agree and have modified the limitations section as follows: . "Our assessment was limited to the diagnosis of colorectal cancers in primary position and this might underestimate the epidemiological incidence of the cancer disease but future studies are required to ascertain this issue. Another limitation of our study is that there were missing charts with respect to the estimated sample size. However, the number of missing charts was very low for Umbria and FVG (ranged from 0% and 2.1%) and quite low for ASL Napoli 3 Sud (6.9% charts missing for colon cancer and 8.5% for rectal cancer). In general, a study population lower than the estimated sample size lead to the same diagnostic accuracy estimates but with broader confidence intervals. Nevertheless, to be more conservative, we also decided to present a "worst case" scenario in which the missing charts were considered as false positives. A potential limitation in our assessment could be the choice of non-cases population that was arbitrary. We chose to select non-cases from an oncological population because we aimed to select a population similar to that of the cases, except having the neoplasm of interest (colon and rectal cancer). In our opinion, using this approach there was a chance of finding false negatives. Choosing the non-cases in other ways, for example from patients with other types of diseases, the chances of finding false negatives would have been very low which was not our primary concern. A possible limitation related to the implications of our results for future research is that validation studies of administrative databases are related to the context in which they are generated and are not generalizable to other settings.".
Conclusion Section:
It would be worthwhile mentioning that this study's contribution concerns three areas (Umbria and Napoli regions and Venezia locality) in Italy and that the results may not be generalizable into other settings. **We agree and modified the Conclusion paragraph as follows: "The present study concerns two regional and local areas in Italy and shows that administrative healthcare databases from Umbria, Napoli and FVG can be used to identify hospitalized subjects with colon and rectal cancer. We proposed a simple case definition for case ascertainment within colorectal cancer and the obtained accuracy is acceptable. The present study will add value to the knowledge of the colorectal cancer diseases given that it covers different areas of Italy and can contribute to improving the cancer treatment patterns, although the presented results may not be generalizable in other settings. ".
Reviewer: 2 Reviewer Name: Alastair Munro Institution and Country: University of St Andrews, Scotland Competing Interests: None declared This paper reports on a validation study of coding for colorectal cancer in 3 regionally based cancer registries in Italy. Patients' case notes were used as the standard against which the accuracy of coding was assessed. The study used randomly selected subsets of patients diagnosed between 2012 and 2014. There were 10207 patients diagnosed with colorectal cancer during the study period, 755 randomly selected patients had case-notes available for review and validation. A total of 560 patients who had cancers coded as arising at non-colorectal sites were used as "controls".
I am unconvinced that the control group that was chosen was appropriate. Patients who were not coded as having cancer might, on review of case-notes, be found to have colorectal cancer. There is no evidence that the authors used age and gender (or any other demographic factors) to match cases (colorectal cancer) with controls. ** We thank Dr. Munro for raising this point that requires a clarification. We did not match subjects with age and gender. In general, in validation studies evaluating administrative databases, there is no agreed method on how to select controls -except in defining them as non-cases, i.e., cases without the code of interest. Our general hypothesis for not choosing controls from subjects that were discharged with any diagnosis from any hospital was that we could have obtained a sensitivity of 100% that was not our aim. Instead, we thought that capturing subjects in an oncological scenario could be a better approach. Despite in the medical literature we did not find studies on how controls were selected in oncological We discussed this point in the manuscript as follows: "A potential limitation in our assessment could be the choice of non-cases population that was arbitrary. We chose to select non-cases from an oncological population because we aimed to select a population similar to that of the cases, except having the neoplasm of interest (colon and rectal cancer). In our opinion, using this approach there was a chance of finding false negatives. Choosing the non-cases in other ways, for example from patients with other types of diseases, the chances of finding false negatives would have been very low which was not our primary concern."
The authors' primary concern appears to be the demonstration that -amongst patients coded as having cancers other than colorectal cancer -there were very few patients who, upon review of their case-notes, were found to have colorectal cancer. Based on the information summarised in table 3, only 7/560 (1.25%) were misclassified ("false negatives"). However, the data presented in Table 3 have a rather more disturbing implication, one that the authors have played down. The figures show that 143/755 (18.9%) patients coded as having colorectal cancer did not, when their case-notes were reviewed, have any clear evidence that they had the disease. Combining information from Tables 2 and 3 it would appear that 77/143(53.8%) had no histology reports in their case-notes and that 65/143(45.5%) had benign disease.
The conclusion that I would draw from this study is that almost 1 in 5 of the patients registered as having colorectal cancer did not, in fact, have any positive evidence of the disease. Furthermore 65/755(8.6%) had unequivocal evidence that they had benign disease. If nearly 10% of patients in these registries have benign disease, then this will artificially inflate any estimates of survival from colorectal cancer based on incidence data provided by these registries. None of these important points are addressed in the discussion. **We would like to thank Dr. Munro very much for raising this important issue, that has allowed us to provide further explanations and statements about (a) our case definition, (b) the number of lesions present within the medical charts that we wrongly overlooked to report and -in this occasionbecomes relevant for explaining the case of false positives. A. The issue of "case definition" Our aim was to determine the accuracy of ICD-9 codes regarding colon and rectal cancer within the case definition: "presence of a lesion + a histological documentation within the first medical chart of the cases". Having a 10% rate of false positives does not necessarily mean that these cases were without the disease of interest. If we had used another algorithm that comprised the evaluation of subsequent medical charts and other elements such as chemotherapy or radiotherapy, we would have obtained a much lower rate of false positives. Our objective was to test a simple case definition and evaluate its accuracy. During the process of validation our main concern was simply to be as rigorous as possible, and left the paper without any further explanation regarding the false positives (such as those classified as adenomas), this is where Dr. Munro's comment comes in. The need for an explanation brings us to the second point.
B. The issue of number of lesions
Again, for the purpose of rigor, we overlooked to report the second lesion(s) in the same patient. Two or more lesions that coexisted in subjects ranged from 10% to 26% in the three operative units. Hence, the coexisting lesions of the adenomas might be malignant cancer. To demonstrate this we did more work by consulting subsequent medical charts for the subjects considered as false positives. Indeed, we have found that several second lesions were indeed a malignant carcinoma.
The issue raised by Dr. Munro could be extended also to the false positives rated as "missing histological documentation". To provide the reader with a real picture of most of these types of false positives, we provided further data regarding the presence of metastases, chemotherapy or radiotherapy (that we retrieved during the evaluation of the initial medical charts) that may support our discussion in the manuscript.
We provided in the Discussion the following comment: "False positive rates, that influenced specificity and PPVs, ranged between 18% and 22% and this may be due to our stringent criteria that the two elements of our case definition had to be present in the first medical chart. Overall we had 143/755 (19%) false positives; however, when considering other elements such as subsequent medical chart consultation, the presence of metastases, and the radiotherapy or chemotherapy treatment, the rate of false positives could be reduced to 68/755 (9%). In addition, 65 of the false positives were considered as negative histology or benign histology of the respective lesions. Part of these lesions were coexisting with other lesion the nature of which (benign or malignant) is unknown owing to missing histological documentation. Should we apply a broader criteria, such as the presence of metastases or the use of chemotherapy or radiotherapy, the number of cases with a negative or benign histology would be reduced to 3%. We are unsure whether these 3% are negative cases for malignant disease but researchers will need to take into account these elements when using administrative databases for future studies. In addition, we found that cases with at least two colorectal lesions were identified varying between 10 to 25% across the three cohorts of subjects. Synchronous colorectal neoplasms, that is two or more primary tumours identified in the same patient and at the same time, has been described in the medical literature with a 33% of rate [2006] . Researchers that aim to validate colorectal cancer ICD-9 codes, will need to make thorough evaluation of the number of lesions and their respective instrumental and histological documentation."
There is no mention of ethical review or permission for access to personal data. **We thank Dr. Munro for raising the ethical issue. We have added information regarding ethical approval in the method section and in the footnotes.
There are several typos, unclear expressions, and cut and paste errors in the manuscript. These include:
P3 13/16: medical chart review as a reference standard to ascertain cases of melanoma cancer ** We thank Dr. Munro for indicating this mistake. We changed "melanoma" with "colorectal" P4: on administrative databases cohort of patient with **We changed the sentence as follow: "Large-scale population based studies have relied on administrative databases of patients with specific diseases".
The process of validation consists in confirming the consistency We reworded as follows: "The process of validation consists in evaluating the consistency of information within the administrative databases and the information contained in the clinical charts, which are generally considered the gold standard".
Pattern and epidemiology of colorectal cancer 14 15 , its treatment either in pharmacologically or surgically **We reworded as follow: "Epidemiology of colorectal cancer and treatment patterns14 15, …"
P6:
The administrative databases target for the present were represented **We reworded as follow: "The administrative databases target of the present study were two regional databases and one local database, represented by the Umbria Region (890,000 residents), the Local Health Unit 3 of Napoli (NA) (1,170,000 residents) and the Friuli Venezia Giulia (FVG) Region (1,227,000 residents)".
code of the residents permits to link the different types of information ** we reworded as follows: "The unique national identification code of the residents permits to link the different types of information within the database, and since the health care is covered almost entirely by the Italian National Health System (NHS) most residents' significant healthcare information can be traced within the healthcare databases. "
P7:
i.e. patients having in primary position a diagnosis of cancer **We reworded as follow: "For controls (non-cases), first subjects aged 18 or higher with diagnosis of cancer disease, i.e., patients having in primary position a diagnosis of cancer (ICD-9 140-239), were identified.".
P11:
All ccuracy results with their **We amend the sentence.
despite in the NA administrative database the specificity was reduced from 80% to 73% (95% CI 64% to 80%) due to the 11 medical charts of the cases. **We reworded as follow: "… despite in the NA administrative database the specificity was reduced from 80% to 73% (95% CI, 64% to 80%) due to the 11 missing medical charts of the cases. ."
P12
In the Netherlands, Helqvist et al. evaluated the validity of ICD-10 colorectal cancer (colon cancer: codes C18; cancer in the colorectal junction: C19; and rectal Cancer: C20) coding in the Danish National Registry of Patients, using the Danish Cancer Registry as a reference standard. We reworded as follows: "In Denmark, Helqvist et al. [Helqvist 2012 ] evaluated the validity of ICD-10 colorectal cancer (C18 for colon cancer, C19 for cancer in the colorectal junction, and C20 for rectal cancer) coding in the Danish National Registry of Patients, using the Danish Cancer Registry as a reference standard."
P14: contribute in improving the cancer care. We reworded the sentence as follow: "The present study will add value to the knowledge of the colorectal cancer diseases given that it covers different areas of Italy and can contribute to improving the cancer treatment patterns, although the presented results may not be generalizable in other settings. ".
P18 Ecoaddome
We reworded as follows: "Abdomen ultrasound"
P21: hystological We corrected as follow: "histological" P24: Sensitivity and specificity with 95% confidence intervals for lung cancer ICD-9-CM codes for the three administrative databases. **we corrected with "colorectal cancer" References ( 
GENERAL COMMENTS REVIEWERS' COMMENTS TO AUTHORS
The authors have answered most of my minor comments. However, I still have concerns about my major comments. I agree with the authors that it would be preferable to determine the accuracy of the colorectal ICD-9 codes based on a specific "case definition" using sensitivity and specificity as accuracy measures, as these measures are intrinsic properties of a test while predictive values are bound to the prevalence of the disease. However, I am still unconvinced by the methodology used for the estimation of these indicators.
Regarding specificity, I am still unconvinced that the control group that was chosen was appropriate. Regarding sensitivity, I understand that the authors do not wish to use registry data as a reference. I agree with the authors that medical records can be considered as a reference. However, I still do not understand how sensitivity, i.e. the probability of having the diagnosis code of cancer in the discharge abstract among a representative sample of ascertained cancer cases could be estimated from their sample. In my opinion, patients selected in administrative databases by the occurrence of diagnosis code of colorectal cancer do not constitute a representative sample of ascertained cancer cases as they may include false positive cases (as suggested by Table 2 ). Moreover, false negative cases (as also suggested by Table 2 ) are not included in this sample.
As a consequence, I think that the authors should explain these difficulties in the Discussion section, and limit their results to the estimation of the positive predictive value.
VERSION 2 -AUTHOR RESPONSE
BMJ Open -Decision on Manuscript ID bmjopen-2017-020630.R1
Editorial Comments:
Thank you for submitting your revision to BMJ Open. As the second reviewer requested major revisions to your paper and did not agree to review this revision, we asked a member of our editorial board with a background in this line of research to provide feedback on your revision.
The editorial board member and reviewer 1 have recommended further revisions to your paper. Therefore, I invite you to respond to their comments and revise your manuscript. Please note that we normally allow a maximum of two manuscript revisions. As such, we urge you to make all the necessary revisions at this stage in an effort to convince the reviewers and editorial team that your work is suitable for publication in BMJ Open.
Please note that while we are willing to consider your next revision, we may need to seek further advice from our editorial board and we cannot predict the outcome of your resubmission at this time.
Editorial Request:
-Please revise your title so that it includes your study design. This is the preferred format for the journal.
We have modified the title to: "Accuracy of colorectal cancer ICD-9-CM codes in Italian administrative healthcare databases: a cross-sectional diagnostic study"
Comments from the Editorial Board:
Given that sensitivity measures the ability of a test to correctly identify those with the disease, you would need to have a complete list of those who really had the disease. I'm not sure that is available to the authors, since as they started, the population based registries in Italy have a low (65%) population coverage. As noted by the reviewers, some people with colorectal cancer are not diagnosed with it (even evidenced by cases diagnosed based on death certificate only).
We thank the Editorial Board for this comment because it may help us to clarify the issue of cancer registries. The population in three areas of interest (Umbria Region, ASL Napoli 3 Sud, and Friuli Venezia Giulia Region) are covered 100% by cancer registries. However, the issue of cancer registries originated from the comments of the reviewers and did not fall within our scope, for this reason our response may have been insufficient in explaining the case and this might have lead to a misunderstanding.
In any case, we would like to highlight here that our study design is a diagnostic accuracy study, in which (a) the population of interest are subjects with colorectal cancer, (b) the index test is represented by the ICD-9 codes of colorectal cancers in primary diagnoses in an administrative database, (c) the reference standard is represented by the medical chart.
Regarding the generalizability of the cases we agree that we need to underline that the ICD-9 code we validated is limited to the primary diagnosis of hospitalized patients. Diagnoses for colorectal cancer could result in secondary position or from a day hospital setting. We have discussed this more in-depth in the revised version of the manuscript as follows: "Our assessment was limited to the diagnosis of colorectal cancers in primary position and this might underestimate future epidemiological incidence of the cancer disease. We are unsure whether the obtained accuracy results can be generalized to new cases of cancer in patients who were diagnosed in day hospital or day surgery facilities. Further research is needed to address the validity of ICD-9 codes in outpatient settings"
I can emphathise with the authors in that the protocol has been previously peer reviewed, so I don't think it is necessary to change the methodology, more just making sure the extent of generalisability is made clear. For example, the "Participants" section in the Abstract does not provide much information about how the cases and controls were selected. This impacts on how the results are viewed.
We very much appreciate your thoughts to maintain the methodology.
We agree with the Editor's comment. We have provided the following amendment to the "Participants" section in the Abstract:
"We randomly selected from each hospital discharge database 130 incident patients, admitted between 2012
and 2014, having colorectal cancer ICD-9 codes located in primary position, and 94 non-cases, i.e. patients having in primary position a diagnosis of cancer (ICD-9 140-239) other than colorectal cancer".
I found Reviewer #2's comment about the 1 in five patients registered as having colorectal cancer but with no medical evidence of the disease very relevant, and seems to conflict with the main findings of the paper.
The author's response to this point was confusing, and seemed to suggest errors in the data collection process. The issues relating to the false positives (which reduce from 19% to 3% through revised methods)
seems to reflect a flaw in the original methodology. Can the authors present the data based on multiple tumours being considered, not just the first lesion?
We regret we were not able to clarify this issue in the last version. Again we thank the Editor for giving us the chance for clarification.
Our main aim was to determine the accuracy of ICD-9 codes relative to colorectal cancer against the medical chart (=reference standard). Whatever their implications, specificities ranged between 78 to 82% and PPVs varied between 80 and 84% across the three operative units.
Having a rate of around 20% false positives does not necessarily mean that these cases were without the disease of interest. This rate is bound to the case definition we provided: i.e., a combination of a colorectal lesion with histological documentation in the first medical chart. Had we used algorithms that comprised the evaluation of subsequent medical charts and other elements such as chemotherapy or radiotherapy, we could have obtained a much lower rate of false positives.
As for the "no medical evidence" in the medical charts, we do not completely agree, as there were other elements that could confirm the presence of malignant cancer that we did not take into account given that our aim was not to prove whether a specific patient had the diagnosis of interest. However, we think that Reviewer #2' criticisms are important and in Table 3 we provided several footnotes that prove that most of the patients classified as 'false positives' had evidence of malignant cancer. At the same time, we have to underline that the rate of false positives did not change in our main findings in both the two previous versions of the manuscript.
We agree that the statement on false positives in the Discussion might be confusing and we replaced it with the following paragraph:
"In some of the cases, the false positives could be explained by the absence of histological documentation in the first medical chart. This does not necessarily mean that patients classified as false positive cases did not have colorectal cancer, since there were several indicators that can prove the presence of malignant cancer.
These include the confirmation of the malignant disease in other sources such as subsequent medical charts, the administration of chemotherapy or radiation therapy, the presence of metastases. A part from three cases that did not perform biopsy due to cachexia or death, there were 15/755 (2%) with negative histology and 4 (0.5%) adenocarcinoma in situ that resulted in important misclassifications (Tables 3 and 4) ".
Regarding the errors in the data collection process. We do not think that there were errors in the data collection, rather there was an incomplete interpretation. Hence, during validation, a patient with two lesions, one malignant and the second benign, was classified as "patient with malignant cancer". However, in case of a patient with one benign lesion and a second lesion without histological examination, the case was assigned as "patient with benign cancer" in our initial assessment. After the considerations of Reviewer #2, we revised our judgement and concluded that we could reasonably consider this last case as "patient with missing histological documentation". From here we state two important things: one is that the case remains a false positive and does not conflict with the main findings; the second is that there were no errors in the data extraction.
Regarding the multiple tumours. Our unit of analysis was the subjects with the disease not the lesion. We are unable to provide accuracy data based on the number of lesions. In any case we clarified that "During the validation process, a subject with two lesions, one benign and the other malignant, was classified as a true positive whereas another with two lesions, one benign and the second with missing histological documentation, was classified as false positive."
REVIEWERS' COMMENTS TO AUTHORS
The authors have answered most of my minor comments. However, I still have concerns about my major comments.
I agree with the authors that it would be preferable to determine the accuracy of the colorectal ICD-9 codes based on a specific "case definition" using sensitivity and specificity as accuracy measures, as these measures are intrinsic properties of a test while predictive values are bound to the prevalence of the disease.
However, I am still unconvinced by the methodology used for the estimation of these indicators.
Regarding specificity, I am still unconvinced that the control group that was chosen was appropriate.
There are no agreed guidelines for ideal situations to select controls. By definition, in a diagnostic study the controls or non-cases are those without the disease of interest. In this sense we think that our controls are appropriate though we have discussed that some limitation might exist.
Regarding sensitivity, I understand that the authors do not wish to use registry data as a reference. I agree with the authors that medical records can be considered as a reference.
* We thank Dr. Quantin for agreeing that medical records can be used as reference standard.
However, I still do not understand how sensitivity, i.e. the probability of having the diagnosis code of cancer in the discharge abstract among a representative sample of ascertained cancer cases could be estimated from their sample. In my opinion, patients selected in administrative databases by the occurrence of diagnosis code of colorectal cancer do not constitute a representative sample of ascertained cancer cases as they may include false positive cases (as suggested by Table 2 ). Moreover, false negative cases (as also suggested by Table 2 ) are not included in this sample.
* We thank Dr. Quantin for this comment. Regarding the representativity of the cases we agree that we need to underline that the ICD-9 code we validated is limited to the primary diagnosis of hospitalized patients.
Diagnoses for colorectal cancer could result in secondary position or from a day hospital setting. We have better discussed this in the revised version of the manuscript as follows: "Our assessment was limited to the diagnosis of colorectal cancers in primary position and this might underestimate future epidemiological incidence of the cancer disease. We are unsure whether the obtained accuracy results can be generalized to new cases of cancer in patients who were diagnosed in day hospital or day surgery facilities. Further research is needed to address the validity of ICD-9 codes in outpatient settings."
Regarding the sensitivity and false positives.
In our study, sensitivity refers to the proportion of patients with an ICD-9 code for colorectal cancer in the discharge abstract out of the total of patients with colorectal cancer confirmed by the medical chart [TP/(TP+FN)].
Having in mind the 2 x 2 table adapted from table 3, essential to calculate sensitivity, specificity and predictive values, we report below an example of colon cancer in Umbria::
The false positives (25) are derived from the cases and the false negatives (N=1) originates from the control.
We have the impression that we did not sufficiently address the issue of FP. False positives do not necessarily mean that the cases are without the disease. These false positives are bound to the case definition we provided in our method: the presence of a lesion + the presence of histological documentation. Regarding the controls and the PPV this is our comment in the manuscript:
"We chose to report all diagnostic accuracy though we decided to select non-cases from an oncological population because we aimed to select a population similar to that of the cases, except having the neoplasm of interest (colon and rectal cancer). Despite this can be a limitation regarding the accuracy measures of sensitivity and specificity, our overall results comprises also PPVs which are based exclusively on the cases indicating the ability of the administrative database to identify correctly the subjects with disease according to our case definition that varied between 80 and 84%." Table 5 . Tables and accuracy measures for different case definition algorithms.
